ReviewCells2020
Point-of-Care Tests for Hepatitis B: An Overview.
Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 56 citations in OpenAlex.
- Assessing the feasibility, acceptability and impacts of an education program on hepatitis B testing uptake among ethnic Chinese in Australia: results of a randomised controlled pilot study.BMC public health · 2021Trial
- Evaluation of fingerstick blood point-of-care testing of hepatitis B DNA for enhanced hepatitis B treatment decision making: a diagnostic accuracy study.Journal of clinical microbiology · 2026Article
- Development and Optimization of a Quantum Dot-Based Lateral Flow Assay for Hepatitis B Surface Antigen Detection.ACS omega · 2026Article
- Occult hepatitis B virus infection among hepatitis B surface antigen negative vaccinated healthcare workers in East Gojjam zone hospitals.Scientific reports · 2026Article
- The Use of Virus-like Particles as Immunogens to Treat Infectious Diseases.Current topics in medicinal chemistry · 2026Review
- Enhancing Hepatitis B case finding through tech-enhanced community pharmacy: Results from a trial program in Vietnam.PLOS global public health · 2026Article
- Article
- Hepatitis B and C landscape in Uzbekistan: epidemiological patterns revealed in a study of 1 040 000 people.European journal of public health · 2025Article
- Article
- Impact of Point-of-Care Testing on Diagnosis, Treatment, and Surveillance of Vaccine-Preventable Viral Infections.Diagnostics (Basel, Switzerland) · 2025Review
- Reaching Syrian migrants through Dutch municipal registries for hepatitis B and C point-of-care testing.PloS one · 2025Article
- Article
- Uptake of the hepatitis B vaccine among brothel-based female sex workers in Kampala, Uganda.BMC public health · 2024Article
- Antenatal Screening for Hepatitis B Virus in Uganda: Missed Opportunities for Diagnosis and Treatment.Open forum infectious diseases · 2024Article
- Article
- Geographical Access to Point-of-care diagnostic tests for diabetes, anaemia, Hepatitis B, and human immunodeficiency virus in the Bono Region, Ghana.BMC health services research · 2024Article
- Viral hepatitis testing and treatment in community pharmacies: a systematic review and meta-analysis.EClinicalMedicine · 2024Article
- Community-based screening enhances hepatitis B virus linkage to care among West African migrants in Spain.Communications medicine · 2023Article
- The importance of triple panel testing for hepatitis B and the burden of isolated anti-hepatitis B core antibodies within a community sample.Journal of virus eradication · 2023Article
- Impact of COVID-19 on hepatitis B screening in Sierra Leone: insights from a community pharmacy model of care.IJID regions · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the heavy disease burden posed by hepatitis B, around 90% of people living with hepatitis B are not diagnosed globally. Many of the affected populations still have limited or no access to essential blood tests for hepatitis B. Compared to conventional blood tests which heavily rely on centralised laboratory facilities, point-of-care testing for hepatitis B has the potential to broaden testing access in low-resource settings and to engage hard-to-reach populations. Few hepatitis B point-of-care tests have been ratified for clinical use by international and regional regulatory bodies, and countries have been slow to adopt point-of-care testing into hepatitis B programs. This review presents currently available point-of-care tests for hepatitis B and their roles in the care cascade, reviewing evidence for testing performance, utility, acceptability, costs and cost-effectiveness when integrated into hepatitis B diagnosis and monitoring programs. We further discuss challenges and future directions in aspects of technology, implementation, and regulation when adopting point-of-care testing in hepatitis B programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.